Capítulo 1: Fundamentación Teórica
1.4 Estándares de Calidad
1.4.2 CMMI
37204 Transcatheter occlusion or embolization (e.g., for tumor destruction, to achieve hemostasis, to occlude a vascular malformation), percutaneous, any method, non-central nervous system, non-head or neck (Deleted 01/01/2014)
76362 Computerized axial tomographic guidance for, and monitoring of, tissue ablation (deleted 01/01/2007)
76394 Magnetic resonance guidance for, and monitoring of, tissue ablation (deleted 01/01/2007)
76490 Ultrasound guidance for, and monitoring of, tissue ablation (deleted 04/01/2004)
References:
1. Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004; 239(6):818-27.
2. Adam Rene, et al. A comparison of percutaneous cryosurgery and percutaneous
radiofrequency for unresectable hepatic malignancies, Arch Surg 2002; 137: 1332-1339.
3. Al-Asfoor A, Fedorowicz Z, Lodge M. Resection versus no intervention or other surgical interventions for colorectal cancer liver metastases. Cochrane Database Syst Rev 2008;
(2):CD006039.
4. Allison C. Yttrium-90 microspheres (TheraShpere and SIR-Spheres) for the treatment of unresectable hepatocellular carcinoma. Issues Emerg Health Technol 2007; 102: 1-6.
5. Arata MA, Nisenbaum HL, Clark TWI and Soulen MC. Percutaneous radiofrequency ablation of liver tumors with the LeVeen probe: is roll-off predictive of response? J Vasc Interv Radiol 2001; 12:455-458.
6. Awad T, Ghorlund K, Gluud C. Cryotherapy for hepatocellular carcinoma. Cochrane Database Syst Rev 2009; (4):CD007611.
7. Azoulay D, Castaing D, and et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injured liver.
Annals of Surg 2000; 232(5).
8. Bala MM, Riemsma RP, Wolff R et al. Cryotherapy for liver metastases. Cochrane Database Syst Rev 2013; 6:CD009058.
9. Bangash AK, Atassi B, Kaklamani V et al. 90Y radioembolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 2007;
18(5):621-8.
10. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors.
Cancer. 1995;76(9):1665-1670.
11. Berber E, Siperstein A. Local recurrence after laparoscopic radiofrequency ablation of liver tumors: An analysis of 1032 tumors. Ann Surg Oncol 2008; 15(10):2757-64.
12. Bertot LC, Sato M, Tateishi R et al. Mortality and complication rates of percutaneous ablative techniques for the treatment of liver tumors: a systematic review. Eur Radiol 2011;
21(12):2584-96.
13. Biselli M, Andreone P, Gramenzi A, et al. Transcatheter arterial chemoembolization therapy for patients with hepatocellular carcinoma: a case-controlled study. Clin Gastroenterol Hepatol. 2005;3(9):918-925.
14. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC).
Cryosurgical ablation of unresectable hepatic tumors. TEC Assessments 2000; Volume 15, Tab 14.
15. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC).
Radiofrequency ablation of unresectable hepatic tumors. TEC Assessments 2003: Volume 18, Tab 13.
16. Boehm LM, Jayakrishnan TT, Miura JT, et al. Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. Sep 1 2014.
17. Brown KT, Koh By, and et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Interv Radiol 1000; 10(4): 397-403.
18. Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol 2008; 43(6): 727-735.
19. Burger I, Hong K, Schulick R et al. Transcatheter arterial chemoembolization in
unresectable cholangiocarcinoma: Initial experience in a single institution. J Vasc Interv Radiol 2005; 16(3):353-61.
20. Cao CQ, Yan TD, Bester L et al. Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 2010; 97(4):537-43.
21. Carr BI, Kondragunta V, Buch SC et al. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma. A two cohort study. Cancer 2010; 116(5):1305-14.
22. Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: A randomized controlled trial. JAMA, April 2008; 299(14): 1669-1677.
23. Cho YK, Kim JK, Kim MY et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49(2):453-9.
24. Choi GH, Kim DH, Kang CM et al. Is preoperative transarterial chemoembolization needed for a resectable hepatocellular carcinoma? World J Surg 2007; 31(12):2370-7.
25. Choi H, Loyer EM, DuBrow RA and et al. Radio-frequency ablation of liver tumors:
assessment of therapeutic response and complications. RadioGraphics 2001; 21:S41-S54.
26. Chua TC, Liauw W, Saxena A et al. Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma. Liver Transpl 2009;
30(2):166-74.
27. Chung MH, Pisegna J, Spirt M et al. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 2001; 130(6):954-62.
28. Cianni R, Pelle G, Notarianni E et al. Radioembolization with (90) Y-labelled resin microspheres in the treatment of liver metastasis from breast cancer. Eur Radiol 2013;
23(1):182-9.
29. Cirocchi R, Trastulli S, Boselli C et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev 2012; 6:CD006317.
30. Clavien PA, Kang KJ, Selzner N et al. Cryosurgery after chemoembolization for
hepatocellular carcinoma in patients with cirrhosis. J Gastrointest Surg 2002; 6(1):95-101.
31. Coldwell DM, Kennedy AS, Nutting CW. Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer. Int J Radiat Oncol Biol Phys 2007;
69(3):800-4.
32. Curley SA. Radiofrequency ablation of malignant liver tumors. The Oncologist 2001;
6:14-23.
33. DeVita Jr VT, Lawrence TS and Rosenberg SA. The Cancer Journal. The Journal of Principles and Practice of Oncology. March/April 2010, Vol. 16, No. 2.
34. Ding J, Jing X, Liu J et al. Comparison of two different thermal techniques for the treatment of hepatocellular carcinoma. Eur J Radiol 2013; 82(9):1379-84.
35. Ding J, Jing X, Liu J et al. Complications of thermal ablation of hepatic tumours:
comparison of radiofrequency and microwave ablative techniques. Clin Radiol 2013;
68(6):608-15.
36. Duan C, Liu M, Zhang Z et al. Radiofrequency ablation versus hepatic resection for the treatment of early-stage hepatocellular carcinoma meeting Milan criteria: a systematic review and meta-analysis. World J Surg Oncol 2013; 11(1):190.
37. Elias D, Goere D, Leroux G et al. Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 2009; 35(10):1092-7.
38. Feng Q, Chi Y, Liu Y et al. Efficacy and safety of percutaneous radiofrequency ablation versus surgical resection for small hepatocellular carcinoma: a meta-analysis of 23 studies.
J Cancer Res Clin Oncol 2015.
39. Feng K, Yan J, Li X et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol 2012;
57(4):794-802.
40. Fiorentini G, Aliberti C, Tilli M et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32(4):1387-95.
41. Gervais DA, Goldberg SN, Brown DB et al. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc
Interv Radiol 2009; 20(1):3-8. Available online at:
www.sirweb.org/clinical/cpg/PS_on_Percutaneous_RF_for_the_Treatment_of_Liver_Tum ors.pdf.
42. Gonsalves CF, Eschelman DJ, Sullivan KL et al. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J
Roentgenol 2011; 196(2):468-73.
43. Gruenberger T, Jourdan JL, Zhao J et al. Reduction in recurrence risk for involved or inadequate margins with edge cryotherapy after liver resection for colorectal metastases.
Arch Surg 2001; 136(10):1154-7.
44. Guenette JP, Dupuy DE. Radiofrequency ablation of colorectal hepatic metastases. J Surg Oncol 2010; 102(8):978-87.
45. Gulec SA, Mountcastle TS, and et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. 70th Annual Meeting Southeastern Surgical Congress. February 2002.
46. Gupta S, Yao JC, Ahrar KHae et al. Anderson experience. Cancer J 2003; 9(4):241-3.
47. Gupta S, Yao JC, Ahrar K, et al. Hepatic artery embolization chemoembolization, for treatment of patients with metastatic carcinoid tumors: the M. D. Anderson experience.
Cancer J. 2003;9(4):241-243.
48. Gurusamy KS, Ramamoorthy R, Sharma D et al. Liver resection versus other treatments for neuroendocrine tumours in patients with respectable liver metastases. Cochrane Database Syst Rev 2009; (2):CD0076060.
49. Haug AR, Heinemann V, Bruns CJ et al. 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres. Eur J Nucl Med Mol Imaging 2011; 38(6):1037-45.
50. Haug AR, Tiega Donfack BP, Trumm C et al. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med 2012; 53(3):371-7.
51. Herber S, Otto G, Schneider J et al. Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Intervent Radiol 2007;
30(6):1156-65.
52. Hoffmann RT, Paprottka PM, Schon A et al. Transarterial hepatic yttrium-90
radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol 2012; 35(1):105-16.
53. Hong K, McBride JD, Georgiades CS et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol 2009; 20(3):360-7.
54. Huang A, McCall JM, Weston MD et al. Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 2002; 89(3):303-10.
55. Huang YZ, Zhou SC, Zhou H et al. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60(127).
56. Huppert PE, Fierlbeck G, Pereira P et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 2010; 74(3):e38-44.
57. Ibrahim SM, Mulcahy MF, Lewandowski RJ et al. Treatment of unresectable
cholangiocarcinoma using yttrium-90 microspheres: results from a pilot study. Cancer 2008; 113(8):2119-28.
58. Jaeck D, Oussoultzoglou E, Bachellier P et al. Hepatic metastases of gastroenterohepatic neuroendocrine tumors: safe hepatic surgery. World J Surg 2001; 25(6):689-92.
59. Jagad RB, Koshariya M, et al. Laparoscopic microwave ablation of liver tumors: Our experience. Hepatogastroenterology, Jan-Feb 2008; 55(81): 27-32.
60. Jakobs TF, Hoffmann RT, Dehm K et al. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases. J Vasc Interv Radiol 2008;
19(8):1187-95.
61. Jakobs TF, Hoffmann RT, Fischer T et al. Radioembolization in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 2008; 19(5):683-90.
62. Jakobs TF, Hoffmann RT, Schrader A et al. CT-guided radiofrequency ablation in patients with hepatic metastases from breast cancer. Cardiovasc Intervent Radiol 2009; 32(1):38-46.
63. Jones RL, McCall J, Adam A et al. Radiofrequency ablation is a feasible therapeutic option in the multi-modality management of sarcoma. Eur J Surg Oncol 2010; 36(5):477-82.
64. Joosten J, Jager G, Oyen W et al. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005; 31(10):1152-9.
65. Kaibori M, Tanigawa N, Kariya S, et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolization for hepatocellular carcinoma. Dig Dis Sci.
May 2012; 57(5):1404-1412.
66. Kemeny N. Management of liver metastases from colorectal cancer. Oncology (Williston Park) 2006; 20(10):1161-76.
67. Kennedy AS, Coldwell D, Nutting C et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 2006; 65(2):412-25.
68. Kennedy AS, Dezarn WA, McNeillie P et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 2008; 31(3):271-9.
69. Kennedy A, Nag S, Salem R et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007; 68(1):13-23.
70. Kennedy AS, Nutting C, Jakobs T et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest 2009; 27(6):682-90.
71. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J 2010; 16(2):163-75.
72. King J, Quinn R, Glenn DM et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113(5):921-9.
73. Klingenstein A, Haug AR, Zech CJ et al. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol 2013;
36(1):158-65.
74. Knuppel M, Kubicka S, Vogel A et al. Combination of conservative and interventional therapy strategies for intra- and extrahepatic cholangiocellular carcinoma: a retrospective survival analysis. Gastroenterol Res Pract 2012; 2012:190708.
75. Korpan NN. Hepatic cryosurgery for liver metastases: long term follow-up. Ann Surg.
1997; 225(2): 193-201.
76. Kornprat P, Jarnagin WR, DeMatteo RP et al. Role of intraoperative thermoablation
combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 2007; 142(11):1087-92.
77. Kulik LM, Carr BI, Mulcahy MF et al. Safety and efficacy of 90Y radiotherapy for
hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47(1-Jan):71-81.
78. Lang EK, Brown CL. Colorectal metastases to the liver: selective chemoembolization.
Radiology. 1993; 189(2):417-422.
79. Lawes D, Chopada A, Gillams A et al. Radiofrequency ablation (RFA) as a cytoreductive strategy for hepatic metastasis from breast cancer. Ann R Coll Surg Engl 2006; 88(7):639-42.
80. Lencioni R, Crocetti L, Cioni D et al. Percutaneous radiofrequency ablation of hepatic colorectal metastases: technique, indications, results, and new promises. Invest Radiol 2004; 39(11):689-97.
81. Lewandowski RJ, Kulik LM, Riaz A et al. A comparative analysis of transarterial
downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.
Am J Transplant 2009; 9(8):1920-8.
82. Leyendecker JR and Dodd GD. Minimally invasive techniques for the treatment of liver tumors. Medscape, May 2001, www.medscape.com/viewarticle/410856_print. Accessed October 9, 2009.
83. Li Q, Wang J, Sun Y et al. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis—a randomized study. World J Surg 2006; 30(11):2004-11.
84. Liang P, Wang Y, Yu X and Dong B. Malignant liver tumors: Treatment with percutaneous microwave ablation-complications among cohort of 1136 patients.
Radiology, June 2009; 251(3): 933-940.
85. Liu Y, Li S, Wan X et al. Efficacy and safety of thermal ablation in patients with liver metastases. Eur J Gastroenterol Hepatol 2013; 25(4):442-6.
86. Llovet JM, Real MI, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 2002; 359: 1734-9.
87. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;
35(5):1164-71.
88. Lorentzen T, Skjoldbye BO, Nolsoe CP. Microwave Ablation of Liver Metastases Guided by Contrast-Enhanced Ultrasound: Experience with 125 Metastases in 39 Patients.
Ultraschall Med 2011; 32(5):492-96.
89. Loveman E, Jones J, Clegg AJ et al. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Health Technol Assess 2014; 18(7): vii-viii, 1-283.
90. Lu MD, Xu HX, Xie XY et al. Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study. J Gastroenterol 2005;
40(11):1054-60.
91. Mabed M, Esmaeel M, El-Khodary T et al. A randomized controlled trial of transcatheter arterial chemoembolization with lipiodol, doxorubicin and cisplatin versus intravenous doxorubicin for patients with unresectable hepatocellular carcinoma. Eur J Cancer Care 2009; 18(5):492-9.
92. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma:
Which technique is more effective? A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol 2007; 30(1): 6-25.
93. Martin RC, Scoggins CR, McMasters KM. Safety and efficacy of microwave ablation of hepatic tumors: a prospective review of a 5-year experience. Ann Surg Oncol 2010;
17(1):171-8.
94. Masaki T, Morishita A, Kurokohchi K and Kuriyama S. Multidisciplinary treatment of patients with hepatocellular carcinoma. Expert Rev Anticancer Ther, October 2006; 6(10):
1377-1384.
95. Mazzaglia PJ, Berber E, Milas M et al. Laparoscopic radiofrequency ablation of
neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival.
Surgery 2007; 142(1):10-9.
96. McKay A, Dixon E, Taylor M. Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 2006; 93(10):1192-202.
97. McWilliams JP, Yamamoto S, Raman SS et al. Percutaneous ablation of hepatocellular carcinoma: current status. J Vasc Interv Radiol 2010; 21(8 suppl):S204-13.
98. Meloni MF, Andreano A, Laeseke PF et al. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation—intermediate and long-term survival rates.
Radiology 2009; 253(3):861-9.
99. Memon K, Lewandowski RJ, Mulcahy MF et al. Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 2012; 83(3):887-94.
100. Michl M, Haug AR, Jakobs TF et al. Radioembolization with Yttrium-90 Microspheres (SIRT) in Pancreatic Cancer Patients with Liver Metastases: Efficacy, Safety and Prognostic Factors. Oncology 2014; 86(1):24-32.
101. Mocellin S, Pilati P, Lise M and Nitti D. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: The end of an era? J Clin Oncol 2007; 25(35): 5649-5654.
102. Molinari M, Kachura JR, Dixon E, et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol). 2006;18(9):684-692.
103. Mouli S, Memon K, Baker T et al. Yttrium-90 radioembolization for intrahepatic cholangiocarcinoma: safety, response, and survival analysis. J Vasc Interv Radiol 2013;
24(8):1227-34.
104. Mulcahy MF, Lewandowski RJ, Ibrahim SM et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009; 115(9):1849-58.
105. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology.
www.nccn.org/professionals/physician_gls/default.asp.
106. National Cancer Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Available online at:
www.nccn.org/professionals/physician_gls/f_guidelines.asp#site.
107. National Comprehensive Cancer Network. Colon cancer. Clinical practice guidelines in oncology, V2. 2015. WWW.nccn.org/professionals/physician_gls/PDF/colon.pdf.
108. National Comprehensive Cancer Network. Hepatobiliary cancer. Clinical practice guidelines in oncology, V2. 2015.
WWW.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf.
109. National Comprehensive Cancer Network. Neuroendocrine Tumors. Clinical practice guidelines in oncology, V1. 2015.
WWW.nccn.org/professionals/physician_gls/PDF/neuroendocrine.pdf.
110. National Institute for Clinical Excellence (NICE). Radiofrequency ablation for colorectal liver metastases-guidance (IPG327). 2009. Available online at:
guidance.nice.org.uk/IPG327.
111. National Institute for Clinical Excellence (NICE). Radiofrequency ablation of
hepatocellular carcinoma (IPG327). 2003. Available online at: guidance.nice.org.uk/IPG2.
112. Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol 2010; 37(2):118-26.
113. Ng KM, Chua TC, Saxena A et al. Two decades of experience with hepatic cryotherapy for advanced colorectal metastases. Ann Surg Oncol 2012; 19(4):1276-83.
114. Niu R, Yan TD, Zhu JC et al. Recurrence and survival outcomes after hepatic resection with or without cryotherapy for liver metastases from colorectal carcinoma. Ann Surg Oncol 2007; 14(7):2078-87.
115. Obed A, Beham A, Pullmann K et al. Patients without hepatocellular carcinoma
progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13(5):761-7.
116. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011; (3):CD004787.
117. Ong SL, Gravante G, Metcalfe MS et al. Efficacy and safety of microwave ablation for primary and secondary liver malignancies: a systematic review. Eur J Gastroenterol Hepatol 2009; 21(6):599-605.
118. Osborne DA, Zervos EE, Strosberg J et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors.
Ann Surg Oncol 2006; 13(4):572-81.
119. Paprottka PM, Hoffmann RT, Haug A et al. Radioembolization of symptomatic,
unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Intervent Radiol 2012; 35(2):334-42.
120. Park SY, Kim JH, Yoon HJ et al. Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 2011; 66(4):322-8.
121. Patel K, Sullivan K, Berd D et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res 2005; 15(4):297-304.
122. Pathak S, Jones R, Tand JMF, et al. Ablative therapies for colorectal liver metastases: a systematic review. Colorectal Dis 2011; 13(9):e252-65.
123. Pawlik TM, Vauthey JN, Abdalla EK et al. Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver. Arch Surg 2006; 141(6):537-44.
124. Piduru SM, Schuster DM, Barron BJ et al. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. J Vasc Interv Radiol 2012; 23(7):943-8.
125. Pomfret EA, Washburn K, Wald C et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;
16(3):262-78.
126. Pusceddu C, Sotgia B, Fele RM et al. Treatment of bone metastases with microwave thermal ablation. J Vasc Interv Radiol 2013; 24(2):229-33.
127. Qi X, Tang Y, An D et al. Radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Clin Gastroenterol 2014; 48(5):450-7.
128. Rhee TK, Lewandowski RJ, Liu DM et al. 90Y radioembolization for metastatic
neuroendocrine liver tumors: Preliminary results from a multi-institutional experience. Ann Surg 2008; 247(6):1029-35.
129. Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: A novel approach to increase safety and efficacy of radioembolization. Int J Radiation Oncology Biol Phys 2010.
130. Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol 2013; 24(8):1209-17.
131. Rose DM, Allegra DP, and et al. Radiofrequency ablation: a novel primary and adjunctive ablative technique for hepatic malignancies. Annual meeting of the Southern California Chapter of the American College of Surgeons, January 1999.
132. Rosenbaum CE, Verkooijen HM, Lam MG et al. Radioembolization for treatment of salvage patients with colorectal cancer liver metastases: a systematic review. J Nucl Med 2013; 54(11):1890-5.
133. Ruers TJ, Joosten J, Jager GJ et al. Long-term results of treating hepatic colorectal metastases with cryosurgery. Br J Surg 2001; 88(6):844-9.
134. Ruers TJ, Joosten JJ, Wiering B et al. Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. Ann Surg Oncol 2007; 14(3):1161-9.
135. Ruutiainen AT, Soulen MC, Tuite CM et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 2007; 18(7):847-55.
136. Salem R, Lewandowski RJ, Mulcahy MF et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes.
Gastroenterology 2010; 138(1):52-64.
137. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma.
Semin Oncol 2010; 37(2):127-38.
138. Saxena A, Bester L, Chua TC et al. Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option. Ann Surg Oncol 2010; 17(2):484-91.
139. Saxena A, Bester L, Shan L et al. A systematic review on the safety and efficacy of
139. Saxena A, Bester L, Shan L et al. A systematic review on the safety and efficacy of